Jinling Pharmaceutical Co Ltd (000919) — Cash Flow-to-Debt Ratio
Jinling Pharmaceutical Co Ltd (000919) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of CN¥74.01 Million could theoretically repay 0% of its total liabilities (CN¥1.18 Billion) in one year. Explore Jinling Pharmaceutical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jinling Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1999–2024)
Historical debt coverage capacity for Jinling Pharmaceutical Co Ltd across 26 annual periods. Also explore balance sheet size of Jinling Pharmaceutical Co Ltd for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Jinling Pharmaceutical Co Ltd (1999–2024)
Year-by-year debt coverage analysis for Jinling Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Jinling Pharmaceutical Co Ltd (000919) total market value.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.12x | CN¥154.19 Million | CN¥1.24 Billion | ▼ -32.3% |
| 2023 | 0.18x | CN¥158.92 Million | CN¥865.58 Million | ▼ -35.4% |
| 2022 | 0.28x | CN¥260.59 Million | CN¥916.30 Million | ▼ -11.1% |
| 2021 | 0.32x | CN¥292.03 Million | CN¥913.10 Million | ▼ -12.7% |
| 2020 | 0.37x | CN¥311.46 Million | CN¥850.43 Million | ▼ -42.3% |
| 2019 | 0.63x | CN¥465.85 Million | CN¥733.62 Million | ▼ -6.5% |
| 2018 | 0.68x | CN¥433.83 Million | CN¥638.90 Million | ▲ +23.1% |
| 2017 | 0.55x | CN¥443.11 Million | CN¥803.11 Million | ▲ +361.9% |
| 2016 | 0.12x | CN¥96.15 Million | CN¥804.90 Million | ▼ -47.9% |
| 2015 | 0.23x | CN¥212.45 Million | CN¥925.73 Million | ▼ -33.3% |
| 2014 | 0.34x | CN¥299.89 Million | CN¥871.24 Million | ▼ -7.4% |
| 2013 | 0.37x | CN¥271.21 Million | CN¥729.94 Million | ▲ +17.4% |
| 2012 | 0.32x | CN¥232.12 Million | CN¥733.12 Million | ▲ +16.0% |
| 2011 | 0.27x | CN¥172.82 Million | CN¥633.01 Million | ▼ -16.4% |
| 2010 | 0.33x | CN¥177.81 Million | CN¥544.47 Million | ▼ -30.6% |
| 2009 | 0.47x | CN¥188.41 Million | CN¥400.59 Million | ▼ -50.0% |
| 2008 | 0.94x | CN¥305.26 Million | CN¥324.25 Million | ▲ +232.4% |
| 2007 | 0.28x | CN¥118.06 Million | CN¥416.86 Million | ▼ -32.4% |
| 2006 | 0.42x | CN¥138.50 Million | CN¥330.39 Million | ▲ +7.6% |
| 2005 | 0.39x | CN¥109.29 Million | CN¥280.42 Million | ▼ -21.3% |
| 2004 | 0.50x | CN¥159.81 Million | CN¥322.83 Million | ▼ -21.7% |
| 2003 | 0.63x | CN¥161.86 Million | CN¥256.06 Million | ▲ +43.9% |
| 2002 | 0.44x | CN¥130.36 Million | CN¥296.79 Million | ▲ +45.6% |
| 2001 | 0.30x | CN¥92.49 Million | CN¥306.54 Million | ▼ -79.0% |
| 2000 | 1.43x | CN¥231.31 Million | CN¥161.37 Million | ▲ +452.4% |
| 1999 | 0.26x | CN¥39.77 Million | CN¥153.24 Million | — |